Welcome to our dedicated page for Rezolute news (Ticker: RZLT), a resource for investors and traders seeking the latest updates and insights on Rezolute stock.
Rezolute, Inc. (Nasdaq: RZLT) is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), including congenital and tumor forms of the condition. The RZLT news feed highlights company announcements, clinical trial updates, regulatory interactions and corporate developments related to its lead antibody therapy, ersodetug.
Investors and followers of Rezolute can use this page to review detailed updates on key Phase 3 programs such as the sunRIZE study in congenital hyperinsulinism and the upLIFT study in tumor hyperinsulinism. Company news has included topline results from sunRIZE, insights into pharmacologic activity and placebo effects in glucose endpoints, and plans to discuss the full dataset with the U.S. Food and Drug Administration under Breakthrough Therapy Designation.
News items also cover the evolution of the upLIFT trial design after alignment with the FDA on a streamlined, single-arm, open-label approach, as well as data from an Expanded Access Program in tumor HI that informed this strategy. In addition, Rezolute regularly reports on financial results, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), participation in healthcare and investor conferences, and leadership appointments that support its development and potential commercialization plans for ersodetug.
By following RZLT news, readers can track how Rezolute communicates progress in its clinical programs, interprets study findings, and engages with regulators and the investment community. This page provides a centralized view of the company’s press releases and related disclosures, offering context for the ongoing development of ersodetug in rare hyperinsulinism indications.
Rezolute (NASDAQ: RZLT) announced an inducement equity grant under Nasdaq Listing Rule 5635(c)(4) made as of September 30, 2025. The company granted options to purchase a total of 125,000 shares of common stock to two new employees.
The options carry a 10-year term, an exercise price of $9.40 per share (the closing price on September 30, 2025), and vest over four years subject to continued service. The awards were approved by the Compensation Committee as a material inducement to accept employment.
Rezolute (Nasdaq: RZLT) reported its Q4 and FY2025 financial results, highlighting significant progress in its hyperinsulinism treatment programs. The company completed enrollment for its Phase 3 sunRIZE trial with 62 participants for congenital hyperinsulinism (HI), with topline results expected in December 2025. Additionally, Rezolute secured FDA alignment for a streamlined Phase 3 upLIFT study for tumor HI, requiring only 16 participants.
Financial highlights include cash position of $167.9M as of June 30, 2025, up from $127.1M year-over-year. R&D expenses increased to $61.5M for FY2025, while net loss widened to $74.4M. The company strengthened its leadership team with the appointment of Dr. Sunil Karnawat as Chief Commercial Officer, bringing extensive rare disease commercialization experience.
Rezolute (NASDAQ:RZLT) has secured FDA alignment for a streamlined Phase 3 trial design of ersodetug in tumor hyperinsulinism (HI). The agency approved significant modifications to the upLIFT study, eliminating the need for a double-blind placebo-controlled trial and reducing the required participants to as few as 16 patients.
The study will now proceed as a single-arm open-label trial, with patient recruitment ongoing in the U.S. and Europe. The FDA will consider Rezolute's pivotal sunRIZE trial in congenital HI as confirmatory evidence, acknowledging ersodetug's broader applicability. Topline data is expected in the second half of 2026, while the sunRIZE trial results are anticipated in December 2025.
Rezolute (Nasdaq: RZLT), a late-stage rare disease company specializing in hypoglycemia treatment caused by hyperinsulinism, has announced its participation in three major upcoming investor conferences in September 2025.
The company will attend the Cantor Global Healthcare Conference (September 3-5), the H.C. Wainwright Global Investment Conference (September 8-10), and the Morgan Stanley Global Healthcare Conference (September 8-10). Management will engage in Fireside Chats and one-on-one meetings with investors during these events.
Rezolute (NASDAQ:RZLT), a late-stage rare disease company, has appointed Sunil Karnawat as Chief Commercial Officer effective August 18, 2025. Karnawat brings over 25 years of experience in global commercialization of biopharmaceuticals and medical devices, including successful launches of four ultra-rare disease products at Ultragenyx.
The appointment comes as Rezolute advances ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism. As part of his compensation package, Karnawat received an inducement stock option grant of 275,000 shares at $6.55 per share, with a four-year vesting schedule.
Rezolute (NASDAQ:RZLT), a late-stage rare disease company specializing in hypoglycemia treatment caused by hyperinsulinism, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
The company's management team will be available for one-on-one meetings with investors during the conference. Interested investors should coordinate with their BTIG representatives to schedule meetings.
Rezolute (NASDAQ:RZLT), a late-stage rare disease company, will present baseline data from its fully enrolled Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism at ENDO 2025. The presentation, scheduled for July 14, 2025, will focus on patient demographics and characteristics from the trial.
The company's Chief Medical Officer highlighted that the presentation will provide insights into the study population and its comparability to the Phase 2 RIZE study. With enrollment complete, topline data is expected in December 2025, marking progress toward a potential new treatment option for patients with limited alternatives.
The company plans to initiate a registrational study for tumor HI patients in mid-2025, with topline results expected in H2 2026. Rezolute will engage with the FDA to discuss the registrational trial and requirements for a BLA filing, aiming to expand ersodetug's indication beyond congenital HI.
The BTD status acknowledges ersodetug's potential to offer substantial improvement over existing treatments for this serious condition, where current standard care often fails to manage persistent hypoglycemia effectively.